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Abstract
Wheat bran extract (WBE) is a food-grade soluble fibre preparation that is highly enriched in arabinoxylan oligosaccharides. In this
placebo-controlled cross-over human intervention trial, tolerance and effects on colonic protein and carbohydrate fermentation were
studied. After a 1-week run-in period, sixty-three healthy adult volunteers consumed 3, 10 and 0 g WBE/d for 3 weeks in a random
order, with 2 weeks’ washout between each treatment period. Fasting blood samples were collected at the end of the run-in period
and at the end of each treatment period for analysis of haematological and clinical chemistry parameters. Additionally, subjects collected
a stool sample for analysis of microbiota, SCFA and pH. A urine sample, collected over 48 h, was used for analysis of p-cresol and phenol
content. Finally, the subjects completed questionnaires scoring occurrence frequency and distress severity of eighteen gastrointestinal
symptoms. Urinary p-cresol excretion was significantly decreased after WBE consumption at 10 g/d. Faecal bifidobacteria levels were sig-
nificantly increased after daily intake of 10 g WBE. Additionally, WBE intake at 10 g/d increased faecal SCFA concentrations and lowered
faecal pH, indicating increased colonic fermentation of WBE into desired metabolites. At 10 g/d, WBE caused a mild increase in flatulence
occurrence frequency and distress severity and a tendency for a mild decrease in constipation occurrence frequency. In conclusion, WBE is
well tolerated at doses up to 10 g/d in healthy adults volunteers. Intake of 10 g WBE/d exerts beneficial effects on gut health parameters.
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Wheat bran extract (WBE) is a food-grade preparation that
is highly enriched in arabinoxylan oligosaccharides (AXOS)
and that is produced by enzymic extraction from wheat bran.
The AXOS in WBE consist of a backbone of b-1,4-linked
D-xylopyranosyl residues (xylose), some of which are mono-
ordi-substitutedat theC(O)2 and/orC(O)3positionwitha-L-ara-
binofuranosyl residues (arabinose)(1–4). Someof thexyloseunits
in the backbone of AXOS carry glucuronic acid at the C(O)2 pos-
ition, whereas some of the arabinose units are ester-linked at the
C(O)5 position with ferulic acid(1–4). The AXOS in WBE form a
heterogeneous mixture of oligosaccharides differing in degree
of polymerisation and degree of substitution of the xylan back-
bone. Besides AXOS, WBE also contains up to 15% glucans
(mainly b-D-(1,3)(1,4)-linked glucan oligomers) and low levels
of proteins, minerals and monosaccharides(5).
AXOS are non-digestible fermentable prebiotic oligosac-
charides that selectively stimulate the growth of bifidobacteria
in vitro (6), in caeca of chickens(7,8), in caeca of rats(9) and in
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the colon of healthy human volunteers(10). The evidence for
AXOS having prebiotic activity has been recently reviewed(11).
Moreover, AXOS consumption decreases the excretion of urin-
ary and faecal p-cresol, a marker of intestinal protein fermen-
tation(10,12). Colonic protein fermentation is often regarded as
detrimental to host health, in particular with respect to colon
toxicity, mutagenicity and carcinogenicity(13). Fermentation
of proteins by the microbiota produces a series of potentially
toxic substances including ammonia, amines, sulfur-contain-
ing compounds and phenolic compounds such as p-
cresol(14–18). p-Cresol, a tyrosine metabolite produced in the
colon by bacterial fermentation, is relevant to health status
since it is considered the prototype of protein-bound uraemic
toxins in chronic kidney disease(19).
In addition to causing a decrease in protein fermentation,
fermentation of AXOS enhances the production of SCFA in
vitro and in rats(9,20,21). SCFA are produced upon saccharolytic
fermentation of carbohydrates and are considered to be
beneficial to the host(22).
Several studies have indicated that SCFA improve the
intestinal barrier function and reduce inflammation mainly
by inhibition of NFkB activation(23). SCFA stimulate epithelial
cell proliferation and differentiation in the large bowel
in vivo (24), and SCFA, butyrate in particular, are the major
energy source for the colonocytes(25). In addition, in vitro
and animal studies have shown an anti-carcinogenic potential
of increased SCFA production(26). Butyrate, in particular, has
received much attention as a potential chemopreventive
agent by inhibiting promotion of neoplastic cells to cancer
or by removing degraded cells from the tissue(27). However,
SCFA are probably not solely responsible for the anti-
carcinogenic potential of wheat dietary fibre as was suggested
by Borowicki et al.(28). SCFA may provide further benefits
beyond their contribution to gut health. For example, acetate
and propionate can modify hepatic lipid metabolism. Propio-
nate serves as a substrate for gluconeogenesis and may inhibit
cholesterol synthesis, whereas acetate is utilised as a substrate
for the synthesis of longer-chain fatty acids(26). A possible role
for increased SCFA production on glucose homeostasis is
supported by the finding that patients lacking a colon after
surgical resection exhibit a reduction in insulin sensitivity(29).
These effects may be due to the fact that SCFA are ligands
for G-protein-coupled receptors expressed on adipocytes,
enteroendocrine L-cells and immune cells(30). Other studies
have reported that SCFA either directly or indirectly activate
AMP-activated protein kinase (AMPK) in the liver(31). AMPK
is a key enzyme in the regulation of energy metabolism, and
its activation increases skeletal muscle glucose uptake(32)
and inhibits hepatic glucose production(33).
Intake of fermentable non-digestible carbohydrates has in
some cases been noted to cause undesired gastrointestinal
effects, including flatulence, abdominal discomfort and
diarrhoea(34). Additionally, the consumption of fermentable
non-digestible carbohydrates, such as inulin and galacto-
oligosaccharides, has been associated in some studies, but
not all, with a number of other gastrointestinal discomfort
effects including acid reflux and heartburn, belching/burping,
borborygmi, colic (spasmodic abdominal pain), laxation and
nausea(35). Such responses, though transient, affect the per-
ception of well-being by consumers and, hence, their accep-
tance of food products containing these fermentable
carbohydrates.
The purpose of the present study was to evaluate the effect
of WBE on gastrointestinal health parameters in healthy adult
volunteers. In the present study, WBE was administered at
different dosages and in a larger study population as com-
pared with previous studies(10,36). Additionally, the effect of
WBE administration on colonic carbohydrate fermentation
was investigated through measurement of faecal levels of
SCFA while previously breath H2 was used to analyse carbo-
hydrate fermentation, and the effect on colonic protein fer-
mentation was analysed through measurement of urinary
and serum levels of phenolic compounds. Tolerance to WBE
was assessed through self-reported scoring by the subjects
on gastrointestinal symptoms. Safety was evaluated by asses-
sing the occurrence of adverse events (AE) and by analysing
the effect on haematological and clinical blood chemistry
parameters.
Experimental methods
Composition of wheat bran extract
WBE (Brana Vitaw 200) was produced from wheat bran by
Fugeia NV, using a procedure based on that described by
Swennen et al.(1). WBE was analysed for the content of
AXOS, the AXOS average degree of polymerisation, its arabi-
nose:xylose ratio, bound ferulic acid and glucuronic acid, glu-
cose as part of poly/oligosaccharides, mannose as part of
poly/oligosaccharides, galactose as part of poly/oligosacchar-
ides, free monosaccharides, moisture, protein and ash by ana-
lytical procedures outlined previously(5). Lipid content was
measured by a Soxhlet method using petroleum ether extrac-
tion according to method ISO 1443 (International Organiz-
ation for Standardization). The presence of mesophilic
bacteria, yeasts, fungi and Salmonella was determined accord-
ing to methods ISO 4833, ISO 7954, ISO 7954 and ISO 6579/
cor1, respectively. The presence of the heavy metals As, Cd,
Pb and Hg was determined according to a Eurofins method
based on ISO 17 294-1/2.
Table 1 shows the composition of the WBE preparation
used in the present study. It consisted of 79·0 % AXOS (on a
DM basis), had an average degree of polymerisation of 5
and an arabinose:xylose ratio of 0·19.
Subjects
Based on the dataset of an earlier human intervention trial
with WBE(10), an evaluable sample size of forty was expected
to provide 80 % power (two-sided, a ¼ 0·05) for detecting a
statistically significant difference in faecal bifidobacteria
levels (the primary outcome variable of the present study)
between WBE treatment and placebo treatment. Based on
this power analysis, it was decided to recruit approximately
sixty volunteers for the present trial. A total of sixty-three
healthy subjects (thirty women and thirty-three men, mean
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age 42 (SD 17) years, mean BMI 23·3 (SD 3·2) kg/m2, all of Cau-
casian ethnicity) participated in the study. The population
encompassed healthy adult subjects of different age groups:
twenty-five individuals were aged between 18 and 30 years,
five were aged 31–40 years, eight were aged 41–50 years,
fourteen were aged 51–60 years and eleven were aged 61–
85 years. Exclusion criteria were using a low-energy diet or
other extreme dietary habits in the 6 weeks before the start
of the clinical trial, intake of antibiotics in the 3 months
before the start of the clinical trial, intake of medication or
dietary supplements influencing gastrointestinal tract pro-
cesses in the 2 weeks before the start of the clinical trial,
abdominal surgery in the past (with the exception of appen-
dectomy), serious illness (defined as more than 2 weeks
unable to work) in the 3 months before the start of the clinical
trial, complete anaesthetics in the month before the start of the
clinical trial, history of chronic gastrointestinal conditions such
as inflammatory bowel disease and irritable bowel syndrome,
allergy to wheat products, coeliac disease, alcohol abuse, or
smoking of more than five cigarettes per d. Female volunteers
were excluded if pregnant or lactating. During the study, the
subjects ate their usual diet, but were asked to have a regular
eating pattern (three meals per d). The intake of food sub-
stances containing probiotics and/or prebiotics was forbidden.
At the time of inclusion, all subjects were informed about pro-
and prebiotics and the food products containing them. The
subjects were asked to read food labels carefully to check
the content for the addition of pro- and/or prebiotics. The pre-
sent study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the Ethics Committee
of the University Hospital UZ Leuven, Belgium (approval no.
ML5282). Written informed consent was obtained from all sub-
jects. Compliance was assessed by inquiry and by counting the
returned bottles at the end of each intervention. Non-compli-
ance was defined as not taking 100 % of the required drinks
during at least 16 of the 21 d treatment period and/or not
taking 100 % of the required drinks during at least 2 of the 3
last days before stool collection.
Study design
Figure 1 presents a schematic overview of the randomised,
placebo-controlled, double-blind, cross-over study. The
study started with a 1-week run-in period, followed by three
3-week treatment periods with 2-week washout periods in
between two consecutive treatment periods. Each subject
underwent three treatment periods. During the treatment
periods, the following treatments were applied, yet not
necessarily in this order: placebo treatment; treatment with
WBE at 3 g/d (low WBE dose, which equals 2·4 g AXOS/d);
and treatment with 10 g WBE/d (high WBE dose, which
equals 8 g AXOS/d). Clinic visits took place at the end of the
run-in period and at the end of each treatment period. WBE
and placebo were administered as non-carbonated soft
drinks, of which the volunteer had to drink twice daily
70 ml, once after breakfast and once after dinner. Consumption
WOP2
Treatment
period 1
Treatment
period 2
Treatment
period 3
WOP1
Placebo 3 g WBE/d 10 g WBE/d
3
weeks
3
weeks
3
weeks
2
weeks
2
weeks
RI
1
week
Sample collection:
• Blood samples
• Urine (48 h)
• Faeces
Questionnaire:
• GI symptoms
• Bowel habits diary
• 3 d diet diary
x x x x
x x x x
x x x xx x x x
x x x xx x x x x x x x x x
x x x xx x x x
xx xx xx xx
Fig. 1. Schematic representation of the study design. The study started with a 1-week run-in (RI) period, followed by three 3-week treatment periods in which
wheat bran extract (WBE) was taken in by the subjects at a dose of 0 g/d (placebo), 3 g/d and 10 g/d (not necessarily in this order). Blood, urine and faecal
samples were taken at different, indicated, time points. The subjects completed weekly a questionnaire assessing the occurrence frequency and distress severity
of eighteen gastrointestinal symptoms. Additionally, subjects recorded in the bowel habits diary the number of bowel movements and stool consistency during the
1-week RI period and during the last week of each 3-week treatment period. WOP, washout period; GI, gastrointestinal.
Table 1. Characterisation of the wheat bran extract preparation
Composition
AXOS (% DM) 79·0
Of which xylo-oligosaccharides (XOSDP 2–9) (% DM) 39·5
Of which xylobiose (XOSDP 2) (% DM) 22·2
Average DP of AXOS 5
A:X ratio of AXOS 0·19
Glucuronic acid bound to AXOS (% DM) 1·0
Ferulic acid bound to AXOS (% DM) 1·5
Glucose as part of poly/oligosaccharides (% DM) 12·2
Galactose as part of poly/oligosaccharides (% DM) 1·5
Total free monosaccharides (% DM) 0·5
Protein (N £ 6·25) (% DM) 0·6
Total lipids (% DM) ,0·5
Ash (% DM) 0·2
DM (%) 96·4
AXOS, arabinoxylan oligosaccharides; XOS, xylo-oligosaccharides; DP, degree of
polymerisation; A:X ratio, arabinose:xylose ratio.
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of the soft drinks took place at the volunteers’ home. The
WBE-containing soft drinks contained sucrose, colorant, fla-
vour, citric acid and potassium sorbate. The placebo soft
drink had the same composition as the WBE-containing soft
drink, except that WBE was omitted and that 0·25 g tricalcium
phosphate per litre was added to mimic the turbidity of the
WBE-containing soft drinks. Subjects were randomly assigned
to one of six randomisation groups, each randomisation group
differing in the treatment sequence by which the three types
of drinks were to be consumed. A list of unique three-digit
numbers (volunteer numbers) was generated in a random
way. Each volunteer number was linked with the number
of a randomisation group. At the screening visit, an eligible
subject who gave informed consent was randomly assigned
to a volunteer number. Subjects started the study at any of
three different inclusion periods, with the starting date of
the first inclusion period and the starting date of the third
inclusion period being 21 d apart. The study was a double-
blind study. The investigators that had direct contact with
the subjects were blinded to the treatment since they were
unaware of the randomisation groups to which the subjects
were assigned. Moreover, the appearance and the taste of
the different soft drinks were near identical.
Sample collection
Blood samples. At the end of the run-in period and at the
end of each 3-week treatment period, fasting serum and
plasma samples were collected from those thirty-nine volun-
teers who had voluntarily provided consent for drawing
blood during the study. EDTA, lithium heparin and fluoride/
oxalate were used as anti-coagulants. Immediately after
blood collection, plasma and serum were transferred to the
central laboratory facility of the University Hospitals UZ
Leuven for standard analysis of haematology and clinical
chemistry parameters. Samples of EDTA-plasma were stored
at 2208C for the analysis of lipid peroxides. Samples of
serum were stored at 2808C for the analysis of p-cresylsulfate.
Urine samples. From the morning of day 5 until the
morning of day 7 of the run-in period and from the morning
of day 19 until the morning of day 21 of each 3-week treat-
ment period, urine was collected in receptacles containing
1·0 g neomycin. The volume of all urine fractions was
measured and the samples were stored at 2208C until the
analysis of p-cresol and phenol. The completeness of each
urine collection was estimated from the calculation of the
observed:expected creatinine ratio, as proposed by Knuiman
et al.(37). The ratio of the observed:expected creatinine
excretion was calculated using the formula ((24 h creatinine
(mmol) £ 113 g/mol)/(24 mg/kg £ body weight (kg))) for
males and ((24 h creatinine (mmol) £ 113 g/mol)/(21 mg/
kg £ body weight (kg))) for females(37). When the ratio
was lower than 0·7, the urine collection was considered as
incomplete(37,38), and the corresponding data were omitted
for analysis.
Faecal samples. On the evening of day 5 or during day 6
of the run-in period as well as from the evening of day 19 or
during day 20 of each 3-week treatment period, one bowel
movement was collected and immediately frozen by the sub-
jects. The faecal sample was kept frozen until delivery at the
clinic. After 6 d storage at 2208C at the clinic, the faecal
samples were thawed. Subsequently, 2·5 g were immediately
fixed in paraformaldehyde using the procedure described by
Franks et al.(39) for microbial analysis by fluorescent in situ
hybridisation (FISH). Samples of the faecal samples were
stored at 2208C until the analysis of SCFA, pH and ammonia.
Recording of adverse events
Subjects were asked to record whether they had suffered from
a medical condition (differing from the baseline recordings),
had to take new medication or had to stop taking previously
reported medication. Additionally, at each clinic visit, the sub-
jects were asked these questions. This information was
recorded in the appropriate section of the case report form.
Biochemical analyses of blood samples
Haematological parameters, clinical blood chemistry para-
meters (including liver enzymes and parameters of kidney
function), blood lipids, blood vitamins and blood minerals
were analysed using standard laboratory techniques for
blood analysis. Serum p-cresylsulfate content was determined
as described by Meijers et al.(18).
Microbiological analyses of faecal samples
Faecal samples were analysed for composition of the
faecal microbiota. FISH was used to count the number of
different bacterial groups in paraformaldehyde-fixed faecal
samples. Processing of fixed samples and FISH analysis were
performed as described by Franks et al.(39). For total bacterial
cell counts, 40-6-diamidino-2-phenylindole (DAPI) was used.
The probes used for group-specific FISH analysis were
Bif164 for the genus Bifidobacterium (40), Lab158 for the
Lactobacillus–Enterococcus group(41), an equimolar mixture
of Chis150 and Clit135 for the Clostridium histolyticum–
lituseburense group(39), Fprau645 for the Faecalibacterium
prausnitzii group(42) and Rint623 for the Roseburia–Eubacter-
ium rectale group(43). Fluorescent cells were counted as
described earlier(44). Percentage of bifidobacteria was calcu-
lated as the ratio of the absolute amounts of bifidobacteria
to the total bacterial cell count.
Biochemical analyses of faecal samples
Concentrations of the SCFA acetate, propionate and butyrate
were determined as described by Van de Wiele et al.(45),
using 2-methylhexanoic acid as an internal standard. Total
SCFA was defined as the sum of acetate, propionate and
butyrate.
To determine the faecal pH, a sample of approximately 1 g
faeces was homogenised by mixing into 10 % (w/w) deminer-
alised water(46). The pH was immediately measured upon
homogenisation. Ammonia levels were measured on the
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same faecal slurries as used for pH determination, following
the procedure described by Bremner & Keeney(47).
Biochemical analyses of urine samples
Total p-cresol and phenol contents in urinary samples were
determined by GC-MS(48). Creatinine content of urine was
measured using a standard laboratory urinology protocol. p-
Cresol and phenol levels were corrected for creatinine content
(mg p-cresol/g creatinine; mg phenol/g creatinine).
Recording of gastrointestinal symptoms
A questionnaire assessing gastrointestinal symptoms was
established following the guidelines of the US Food and
Drug Administration for the development of patient-reported
outcomes. The following eighteen gastrointestinal symptoms
were scored: diarrhoea, constipation, painful bowel move-
ment, blood in stool, abdominal pain, bloating, abdominal
cramps, abdominal stretching, borborygmy, flatulence, burp-
ing, acid regurgitation, retrosternal burning, nausea, vomiting,
indigestion, difficulty with swallowing and hoarseness/sore
throat. Occurrence frequency of the symptoms was graded
on a five-step scale ranging from never (0), occasionally (1),
frequently (2), nearly always (3) to always (4). Distress sever-
ity of the symptoms was graded on a five-step scale ranging
from no (0), minimal (1), mild (2), moderate (3) to severe
(4) distress, as described by van Munster et al.(49). Subjects
were asked to grade these gastrointestinal symptoms weekly
during the trial.
Recording of stool parameters
During the run-in period and during the last week of every
3-week treatment period, defecation frequency as well as
stool consistency (according to the Bristol Stool Form
Scale(50)) were recorded daily using appropriate question-
naires. Average defecation frequency was calculated as the
number of stools divided by the numbers of days of diary
recording. Average stool consistency was calculated as the
sum of Bristol Stool Form Scales divided by the number of
stools. The composite parameter of defecation frequency
and stool consistency (also called the Bristol Composite
Measure) was calculated as the sum of Bristol Stool Form
Scales divided by the number of days of diary recording(51).
Dietary composition
Subjects were asked to record all food and beverage intake
of days 3–5 of the run-in period and of days 17–19 of each
3-week treatment period. These data were used to calculate
the average daily energy intake (kJ), the average percentage
of energy from carbohydrates, the average percentage of
energy from lipids and the average percentage of energy
from proteins. These calculations were made using the
Nubel Food Planner (www.nubel.be). During treatment with
10 g WBE/d, an additional 218 kJ/d (52 kcal/d) and 9·5 g
carbohydrates/d were added to the reported data; during
treatment with 3 g WBE/d an additional 147·3 kJ/d (35·2
kcal/d) and an additional 7·8 g carbohydrates/d were added
to the reported data; during the placebo treatment period an
additional 117 kJ/d (28 kcal/d) and 7 g carbohydrates/d
were added to the reported data.
Statistical analysis of efficacy variables
All tests of significance were performed at a ¼ 0·05 and two-
sided, unless otherwise stated. Assumptions of normality of
residuals were investigated for each variable using the Sha-
piro–Wilk test(52). When the data were normally distributed,
linear mixed models were applied to the raw data as such,
except for the microbiota data which were log-transformed
before analysis, as is customary for microbiota counts. When
the distribution was not approximated by a normal curve,
values were ranked before analysis and the linear mixed
model was performed on the rank-transformed data(53). Ties
occurring during the rank-transformation were replaced by
their average rank. The data to estimate the fixed-effect par-
ameter for the run-in of the response remained unranked.
Evaluations of the effects of treatment on the efficacy vari-
ables were completed on an efficacy evaluable (EE) popu-
lation, defined as all randomised subjects who received
placebo and at least one serving of at least one WBE-contain-
ing soft drink and who provided at least one post-randomis-
ation outcome data point during each of the two treatment
phases. Subjects who took antibiotics during or before the pla-
cebo treatment period or subjects who took antibiotics during
or before an AXOS treatment period that was not the last treat-
ment period were excluded from the EE population. Addition-
ally, evaluations of the treatment effects on the efficacy
variables were also completed on a per protocol (PP) popu-
lation, a subset of EE subjects who completed the study,
were compliant as defined above, who did not take antibiotics
or other forbidden medications or products and had no major
protocol violations.
Treatment effects as well as treatment £ treatment sequence
and treatment £ inclusion period interaction effects were
tested with linear mixed models using conditional F and t
tests(54) (significance at a ¼ 0·1). The single-step Tukey post
hoc multiple-comparison procedure was used for the pairwise
comparisons of the treatments, using R’s multcomp pack-
age(55). When no significant interactions were found, treat-
ment differences were evaluated based on the main effect
model. In the case of significant interactions, treatment differ-
ences were evaluated within each treatment sequence group
or within each inclusion period group. Next to that, the overall
differences were also analysed by aggregating over the inter-
action effects in the model. Aggregation over the interaction
effects was done by setting up a linear combination of the
treatment differences for each treatment sequence group
and/or inclusion period group, giving equal weights to
either treatment sequence group and/or inclusion period
group. Efficacy results are presented for the PP population
since no differences between the EE and PP results were
observed.
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Statistical analysis of safety parameters
The safety population was defined as all randomised subjects
who received at least one serving of WBE. Safety was analysed
using the emergent AE and the changes in clinical blood
parameters in the safety population. An AE was attributed to
the treatment period during which the AE started. An AE
that started during a washout period was attributed to the
treatment preceding the specific washout period. In a first
analysis of the changes in clinical blood parameters, the
occurrence of adverse shifts in clinical blood parameters was
determined. For a given subject, a shift in a blood parameter
was considered to be adverse when the blood parameter
value after treatment was either (i) outside the normal range
while the corresponding baseline value of that subject was
within the normal range, (ii) below the normal range while
the corresponding baseline value was above the normal
range or (iii) above the normal range while the corresponding
baseline value was below the normal range. McNemar’s test
was used to compare differences in AE frequencies and
differences in blood parameter adverse shifts among the
three treatments (a ¼ 0·017, Sidak correction for three
comparisons)(56). A second analysis of the clinical blood
parameters was performed as defined for the efficacy analysis,
but applied to the safety population.
Results
Participant characteristics
The disposition of all study participants is presented in Fig. 2. A
total of eighty-eight volunteers were screened and sixty-six
were randomised to any of the six different randomisation
groups. Of these, three volunteers terminated the study
prematurely during the run-in period: two volunteers decided
to terminate the study for personal non-medical reasons; the
third volunteer was asked to terminate the study because of
antibiotic intake during the run-in period. Since these volunteers
did not receive any WBE serving, they were excluded from
the safety population. Hence, sixty-three volunteers were inclu-
ded in the safety population. Of these, fifty-eight were included
in the EE population and fifty-seven in the PP population.
Baseline demographics and anthropometric characteristics
for the PP population are presented for the six randomisation
groups in Table 2. No significant differences could be
observed at baseline between the six randomisation groups
with respect to sex, age, BMI, faecal bifidobacteria level, defe-
cation frequency, cholesterol content, LDL-cholesterol and
TAG content. A significant difference at baseline was observed
for HDL-cholesterol content, indicating that randomisation
with respect to HDL-cholesterol was suboptimal.
Analysis of safety variables
Analysis of emergent adverse events. AE were categorised in
eleven categories according to the National Cancer Institute
Common Terminology Criteria for Adverse Events v3·0
before the unblinding of the study. Statistical analysis of the
AE in the safety population revealed no difference between
the three treatments in frequency of any of the different AE
categories (P.0·1).
Analysis of haematological and clinical chemistry para-
meters. In a first analysis, the occurrence of adverse shifts
in clinical blood parameters was determined in the safety
population. Statistical analysis indicated no significant differ-
ences in occurrence frequency of adverse shifts between the
three treatments (P.0·1).
Volunteers recruited (n 88)
Volunteers randomised
and started study (n 66)
Withdrawal before
randomisation
and study start
(n 22)
Rand. group 2
Included (n 11)
Withdrawn (n 1)*
AB intake (n 2)
In safety pop. (n 10)
In EE pop. (n 9)
In PP pop. (n 8)
Rand. group 3
Included (n 11)
Withdrawn (n 1)*
AB intake (n 1)
In safety pop. (n 10)
In EE pop. (n 9)
In PP pop. (n 9)
Rand. group 4
Included (n 11)
Withdrawn (n 0)
AB intake (n 0)
In safety pop. (n 11)
In EE pop. (n 11)
In PP pop. (n 11)
Rand. group 5
Included (n 11)
Withdrawn (n 1)†
AB intake (n 1)
In safety pop. (n 10)
In EE pop. (n 10)
In PP pop. (n 10)
Rand. group 6
Included (n 11)
Withdrawn (n 0)
AB intake (n 1)
In safety pop. (n 11)
In EE pop. (n 10)
In PP pop. (n 10)
Safety population (n 63)
EE population (n 58)
PP population (n 57)
Rand. group 1
Included (n 11)
Withdrawn (n 0)
AB intake (n 2)
In safety pop. (n 11)
In EE pop. (n 9)
In PP pop. (n 9)
Fig. 2. Volunteer disposition. Rand., randomisation; AB, antibiotics; safety pop., safety population; EE pop., efficacy evaluable population; PP pop., per protocol
population. * Reason for withdrawal: personal, non-medical. † Reason for withdrawal: intake of AB during run-in period.
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A second analysis of the clinical blood parameters was per-
formed as defined for the efficacy analysis, but applied to the
safety population (Table 3).
Conditional F tests showed overall WBE-related significant
treatment effects for four parameters: platelet count, lympho-
cyte percentage, mean corpuscular volume and bicarbonate
(P,0·1). Subsequent pairwise comparisons demonstrated
that the only parameter that was affected by WBE treatment
as compared with placebo treatment was the lymphocyte per-
centage in plasma. Lymphocyte percentage was significantly
lower after treatment with WBA at 3 g/d (34·3 %) than after
the placebo treatment period (36·2 %) (P¼0·045). However,
the lymphocyte percentage in plasma after treatment with
WBA at 10 g/d (33·8 %) was not significantly different from
the lymphocyte percentage in plasma after the placebo treat-
ment period (P.0·1).
Analysis of efficacy variables
Conditional F tests showed overall WBE-related significant
treatment effects for ten parameters (Table 4): level of
bifidobacteria in faeces, percentage of bifidobacteria in
faeces, level of Roseburia–E. rectale in faeces, faecal levels
of acetic acid, propionic acid, butyric acid and total SCFA,
stool pH, percentage stool moisture and urinary p-cresol
levels (P,0·1). The main results of the subsequent
pairwise comparisons of these parameters will be discussed
below.
Levels of faecal microbiota
In the PP population, WBE intake selectively increased
bifidobacteria levels in the faeces (Table 4). Intake of WBE
at 10 g/d increased the average levels of bifidobacteria in the
faeces relative to placebo intake by 0·36 log units
(P,0·001). The average percentage of bifidobacteria relative
to the total bacterial content in faeces upon intake of 10 g
WBE/d increased by over 2-fold relative to placebo intake
(P,0·001), while intake of WBE at 3 g/d tended to increase
the average percentage of bifidobacteria by 1·3-fold
(P¼0·065). The faecal levels of Roseburia–E. rectale group
remained unchanged after WBE intake, as were the faecal
levels of total bacteria, lactobacilli, F. prausnitzii and the
C. histolyticum– lituseburense group.
Biochemical parameters in faeces
Intake of WBE at 10 g/d increased the total level of faecal
SCFA and the levels of acetic acid, propionic acid and butyric
acid by about 8 % relative to placebo intake (P#0·05)
(Table 4). Additionally, at the dose of 3 g/d, WBE significantly
increased faecal propionic acid levels (P¼0·037). Consistently
with the increased faecal SCFA levels, stool pH after intake
of WBE at 10 g/d (pH ¼ 6·93) was significantly lower as com-
pared with the stool pH after placebo intake (pH ¼ 7·10)
(P¼0·039).
WBE intake did not affect the percentage moisture in faeces,
nor did it influence faecal ammonia levels (P.0·1).T
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Urinary and serum levels of phenolic compounds
The completeness of each urine collection was estimated from
the calculation of the observed:expected creatinine ratio as
proposed by Knuiman et al.(34). Of the 188 urine collections,
thirty-one were classified as incomplete and were not taken
into account for the statistical analysis of p-cresol and
phenol excretion. Table 4 shows the effects of WBE and
placebo intake on the urinary levels of phenolic compounds.
In general, p-cresol levels were about four times higher than
phenol levels. WBE intake at the dose of 10 g/d decreased
urinary p-cresol levels by 37 % (P¼0·031). WBE intake did
not influence urinary phenol excretion (P.0·1).
Average serum levels of p-cresylsulfate varied between
12·2 and 15·8 mM. WBE intake did not influence the serum
p-cresylsulfate levels (P.0·1).
Energy intake
In the PP population, WBE intake did not modulate the
average daily energy intake, or the average percentage of
energy from carbohydrates, lipids or proteins (P$0·1).
Table 3. Haematological and clinical blood chemistry parameters during a human intervention study following intake of placebo, wheat bran extract
(WBE) at 3 g/d or WBE at 10 g/d
(Mean values and standard deviations)
Placebo treat-
ment period
3 g WBE/d treat-
ment period
10 g WBE/d
treatment period P*
Mean SD Mean SD Mean SD P1 P2 P3 P4
Haematological parameters
Platelets (109/l) 239·7 34·8 246·4 48·2 235·0 40·8 0·064 0·926 0·207 0·974
Eosinophils (%) 2·9 2·2 3·4 2·4 3·0 2·4 0·764 0·723 0·995 0·795
Packed cell volume 0·4 0·0 0·4 0·0 0·4 0·0 0·826 0·869 0·871 1·000
Hb (g/l) 142 10 141 12 142 13 0·729 0·759 0·819 0·995
Lymphocytes (%) 36·2 9·4 34·3 7·8 33·8 8·9 0·056 0·187 0·739 0·045
MCH (pg) 29·3 1·5 29·5 1·5 29·6 1·3 0·126 0·728 0·355 0·101
MCHC (g/l) 327 10 327 9 329 8 0·843 1·000 0·999 0·901
MCV (fl) 89·5 4·1 90·1 4·6 90·1 4·1 0·039 1·000 0·902 0·689
Monocytes (%) 8·2 2·1 8·7 2·0 8·5 1·7 0·603 0·606 0·994 0·695
MPV (fl) 10·5 0·8 10·5 0·9 10·6 0·9 0·770 0·859 0·716 0·967
Erythrocyte count (109/l) 4·9 0·4 4·8 0·5 4·8 0·5 0·559 0·898 0·507 0·796
Erythrocyte distribution width (%) 13·0 0·6 13·1 0·8 13·1 0·8 0·574 0·568 0·656 0·991
Leucocyte count (109/l) 5·7 1·5 5·6 1·4 5·7 1·6 0·861 0·872 0·998 0·906
Clinical chemistry parameters
Glucose (mg/l) 853 80 862 93 879 89 0·353 0·385 0·442 0·995
Insulin (nM) 38·4 19·2 41·4 22·2 40·8 21·6 0·400 0·935 0·560 0·377
Ca (mg/l) 92 4 93 4 93 5 0·324 0·997 1·000 0·881
Cl (mM) 104·0 2·1 104·3 2·2 104·4 2·0 0·579 0·572 0·992 0·672
Fe (mg/l) 1164 416 1028 444 1017 371 0·244 0·241 0·865 0·549
K (mM) 4·0 0·5 4·1 0·5 4·1 0·4 0·485 0·641 0·872 0·375
Mg (mg/l) 22 1 22 1 22 1 0·957 0·960 0·982 0·996
Na (mM) 141·1 1·5 141·8 2·1 140·7 1·8 0·168 0·678 0·157 0·587
Phosphate (mg/l) 28 6 29 6 30 5 0·614 0·997 1·000 0·999
Bicarbonate (mM) 25·6 2·1 25·8 1·8 25·0 2·1 0·026 0·405 0·019 0·344
Cholesterol (mg/l) 1908 313 1931 342 1928 402 0·415 0·591 0·777 0·247
HDL-cholesterol (mg/l) 649 220 626 187 633 177 0·980 0·987 0·999 0·992
LDL-cholesterol (mg/l) 1083 269 1127 302 1116 363 0·137 0·237 0·760 0·078
TAG (mg/l) 881 423 888 555 893 490 0·640 0·629 0·900 0·892
NEFA (mM) 0·5 0·3 0·4 0·2 0·4 0·2 0·754 0·947 0·982 1·000
g-Glutamyltransferase (U/l) 22·6 16·2 19·3 8·7 22·9 15·9 0·701 0·964 0·609 0·776
Lactate dehydrogenase (U/l) 362·6 63·6 363·6 50·5 364·6 52·8 0·112 0·505 0·492 0·076
Phosphatase (U/l) 149·4 42·8 151·4 38·0 155·3 40·6 0·651 0·811 0·999 0·808
Alanine aminotransferase (U/l) 22·2 9·8 21·0 7·3 21·0 10·4 0·187 0·773 0·149 0·478
Amylase (U/l) 76·6 29·8 76·6 29·4 76·6 31·3 0·430 0·724 0·441 0·893
Aspartate aminotransferase (U/l) 23·8 4·0 23·9 4·8 23·8 6·4 0·914 0·920 0·998 0·900
Creatine kinase (U/l) 105·2 45·5 108·9 58·3 111·6 76·2 0·881 0·937 0·969 0·841
Lipase (U/l) 33·6 7·8 32·9 7·7 32·8 10·0 0·557 0·554 0·935 0·789
Folate (mg/l) 9·9 3·2 9·4 3·2 9·4 3·0 0·117 0·474 0·502 0·070
Vitamin A (mg/l) 597·3 163·6 574·4 142·5 582·4 131·4 0·623 0·980 1·000 1·000
Albumin (g/l) 47·3 2·7 47·2 3·0 47·1 2·9 0·967 0·987 0·991 1·000
Bilirubin (mg/l) 7 3 6 3 6 3 0·431 0·418 0·894 0·722
Total protein (g/l) 77·7 3·9 78·2 4·3 77·4 4·5 0·529 0·981 0·582 0·486
Uric acid (mg/l) 50 11 49 11 49 10 0·995 1·000 0·995 0·994
Creatinine (mg/l) 9 2 8 2 8 2 0·821 0·770 0·840 0·993
Urea (mg/l) 323 76 322 79 332 79 0·861 0·836 1·000 0·833
MCH, mean corpuscular Hb; MCHC, mean corpuscular Hb concentration; MCV, mean corpuscular volume; MPV, mean platelet volume.
*P1 is the P value of the conditional F test for overall WBE-related significant treatment effects; P2, P3 and P4 are the P values for the comparison between WBE at 10 g/d
and placebo, WBE at 10 g/d and WBE at 3 g/d, and WBE at 3 g/d and placebo, respectively.
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Table 4. Efficacy variables during a human intervention study following intake of placebo, wheat bran extract (WBE) at 3 g/d or WBE at 10 g/d
(Mean values and standard deviations)
Placebo treatment
period
3 g WBE/d treatment
period
10 g WBE/d treat-
ment period P*
Mean SD Mean SD Mean SD P1 P2 P3 P4
Dietary analysis
Energy intake
kJ 9478·4 2676·5 10 047·5 2756·0 9857·1 2604·1 0·117 0·357 0·770 0·099
kcal 2265·4 639·7 2401·4 658·7 2355·9 622·4 0·117 0·357 0·770 0·099
% Energy from proteins 14·9 3·6 14·5 3·3 14·5 3·3 0·690 0·991 0·999 0·985
% Energy from carbohydrates 47·3 8·0 48·4 7·9 48·4 8·1 0·432 0·510 0·999 0·487
% Energy from lipids 32·7 7·5 32·0 7·3 32·0 6·7 0·745 0·774 0·999 0·794
Levels of faecal microbiota
Total bacteria (log10 cells/g dry faeces) 10·9 0·3 10·7 0·3 10·8 0·4 0·140 1·000 0·889 0·657
Bifidobacteria (log10 cells/g dry faeces) 8·9 0·6 9·0 0·5 9·3 0·7 0·000 0·000 0·041 0·603
Percentage bifidobacteria 2·4 3·2 3·3 3·6 5·1 4·3 0·000 0·000 0·004 0·065
Lactobacilli (log10 cells/g dry faeces) 5·7 2·2 5·9 2·2 5·4 2·3 0·962 1·000 1·000 1·000
Faecalibacterium prausnitzii (log10 cells/g dry faeces) 9·4 0·6 9·4 0·4 9·4 0·5 0·642 0·749 0·632 0·966
Clostridium histolyticum– lituseburense (log10 cells/g dry faeces) 3·2 1·2 3·7 2·0 3·6 1·8 0·187 0·450 0·850 0·220
Roseburia–Eubacterium rectale (log10 cells/g dry faeces) 9·4 0·9 9·5 0·4 9·5 0·5 0·050 1·000 1·000 1·000
Biochemical parameters of faeces
Acetic acid (mmol/g dry faeces) 454·9 415·7 463·8 336·6 493·4 265·3 0·007 0·003 0·193 0·281
Propionic acid (mmol/g dry faeces) 106·3 88·7 109·2 64·6 116·0 73·4 0·010 0·009 0·882 0·037
Butyric acid (mmol/g dry faeces) 103·0 104·3 99·1 73·5 108·0 75·6 0·069 0·050 0·651 0·308
Total SCFA (mmol/g dry faeces) 664·3 570·1 672·1 451·9 717·4 381·2 0·003 0·001 0·251 0·130
Stool pH 7·1 0·6 7·0 0·5 6·9 0·5 0·053 0·039 0·587 0·311
Moisture (%) 71·2 7·9 72·1 6·7 73·0 6·4 0·081 0·112 0·996 0·135
Ammonia (mg/g dry faeces) 2·1 0·9 2·1 1·0 2·3 1·1 0·858 0·722 0·986 0·813
Levels of phenolic compounds
Urinary p-cresol (mg/g creatinine) 34·2 36·0 29·1 26·7 21·6 18·9 0·034 0·031 0·139 0·843
Urinary phenol (mg/g creatinine) 7·3 9·9 4·9 2·3 5·1 3·3 0·829 0·783 0·905 0·973
Serum p-cresylsulfate (mM) 15·0 12·2 16·2 14·3 12·6 11·1 0·203 0·220 0·315 0·976
Bowel habits
Defecation frequency (no. bowel movements/d) 1·3 0·6 1·3 0·4 1·3 0·5 0·258 0·224 0·750 0·623
Stool consistency (average stool consistency/bowel movement) 3·8 1·1 3·8 1·0 3·8 0·9 0·815 0·863 0·828 0·997
Bristol composite measure (average stool consistency/d) 3·4 1·3 3·4 1·1 3·4 1·1 0·956 0·956 0·889 0·983
Blood lipids
Cholesterol (mg/l) 1901 309 1921 351 1925 404 0·474 0·553 0·924 0·362
HDL-cholesterol (mg/l) 614 159 601 166 615 163 0·976 0·994 0·981 0·996
LDL-cholesterol (mg/l) 1105 272 1141 314 1130 371 0·168 0·258 0·885 0·122
TAG (mg/l) 909 433 895 577 902 503 0·597 0·613 0·949 0·820
*P1 is the P value of the conditional F test for overall WBE-related significant treatment effects; P2, P3 and P4 are the P values for the comparison between WBE at 10 g/d and placebo, WBE at 10 g/d and WBE at 3 g/d, and WBE
at 3 g/d and placebo, respectively.
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Blood lipids
In the PP population, WBE intake did not affect the average
blood levels of either total cholesterol, LDL-cholesterol,
HDL-cholesterol or TAG (P.0·1).
Bowel habits: defecation frequency and stool consistency
WBE intake did not influence the number of bowel move-
ments per d, nor did it modulate stool consistency as
measured using the Bristol Stool Form Scale (P.0·1).
Analysis of tolerability
Tolerability was assessed through self-reported scoring by the
volunteers of the occurrence frequency and distress severity
of eighteen different gastrointestinal symptoms. During treat-
ment with WBA at 10 g/d, both the occurrence frequency and
distress severity of flatulence increased compared with the pla-
cebo treatment (P¼0·02, binary mixed model; P,0·05, Baye-
sian ordinal mixed model) (Fig. 3(a) and (b)). With respect to
occurrence frequency, the largest increase was seen in the
scores ranging between occasionally and regularly, while no
increases were seen in the more severe flatulence occurrence
frequency scores. With respect to distress severity, the largest
increase was seen in the scores ranging between minimally dis-
turbing and mildly disturbing. A slight reduction in occurrence
frequency of constipation was observed upon intake of WBE at
10 g/d compared with placebo intake (P¼0·095; binary mixed
model) (Fig. 4). The subjects that never experienced consti-
pation increased from 81 % during the placebo treatment
period to 91 % during treatment with WBA at 10 g/d
(P¼0·095; binary mixed model). None of the other assessed
gastrointestinal symptoms was affected by WBE intake.
Discussion
WBE consumption during 3 weeks at a daily dosage of 10 g
led to an increase in bifidobacteria counts relative to placebo
intake. Cloetens et al.(10) previously showed that the stimu-
lation of bifidobacteria after WBE intake was most pro-
nounced in subjects with the lowest baseline levels. Since
bifidobacteria levels have been shown to decrease upon
ageing(57,58), we determined the effect of age on faecal bifido-
bacteria levels in two age subgroups: 18- to 50-year subgroup
and $ 51-year subgroup. This analysis showed that intake of
WBE at 10 g/d significantly (P,0·05) increased faecal bifido-
bacteria in both age subgroups (data not shown). In addition,
a statistically significant increase (P,0·05) in bifidobacteria
was found regardless of sex (data not shown).
It is well known that the prebiotic effect of a compound is
strongly affected by the baseline levels of targeted beneficial
bacteria in faeces, in the sense that relatively lower relative
changes are observed upon intake of a prebiotic compound
when the baseline levels are high(59,60). Since the baseline
level of faecal bifidobacteria in the present study was already
high (log10 8·6 cells/g dry faeces), it is not surprising that
the relative increase in faecal levels of bifidobacteria is rela-
tively small. In addition, the change in absolute numbers of
beneficial intestinal bacteria is considered to be more import-
ant for the prebiotic effect than the relative change(60,61).
The 0·4 log increase in faecal bifidobacteria levels after
0
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Fig. 3. (a) Distribution of flatulence occurrence frequency scores. ( ),
Frequency 0 (never); ( ), frequency . 0–1; ( ), frequency . 1–2; ( ), fre-
quency . 2–3. Frequency 1, occasionally; frequency 2, regularly; frequency
3, nearly always; WBE, wheat bran extract. (b) Distribution of flatulence
distress severity scores. ( ), Score 0 (not disturbing); ( ), score . 0–1;
( ), score . 1–2; ( ), score . 2–3; ( ), score . 3–4. Score 1, minimally
disturbing; score 2, mildly disturbing; score 3, moderately disturbing; score 4,
very disturbing.
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Fig. 4. Distribution of constipation occurrence frequency scores. ( ),
Frequency 0 (never); ( ), frequency . 0–1; ( ), frequency . 1–2; ( ), fre-
quency . 2–3. Frequency 1, occasionally; frequency 2, regularly; frequency
3, nearly always; WBE, wheat bran extract.
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intake of WBE observed in the present study amounts to an
increase by an absolute number of about 2 £ 109 cells/g dry
faeces, which is in the same order of magnitude observed in
several other studies reviewed by Roberfroid et al.(60).
We demonstrated that the total levels of faecal SCFA and of
the individual SCFA, acetic acid, propionic acid and butyric
acid, were increased upon intake of WBE at 10 g/d relative
to placebo intake, while an increase of faecal propionic acid
levels already occurred upon intake of WBE at 3 g/d. WBE
appears to increase the faecal level of SCFA at lower doses
than reported for other prebiotic compounds such as inulin
and oligofructose. A number of studies in human volunteers
who consumed oligofructose at high dosages varying from
13 to 20 g/d revealed an increase in faecal concentrations of
acetic acid(62) or total SCFA, acetic acid and propionic
acid(63), but not in butyric acid(62,63). However, consumption
of 20–40 g inulin/d was reported not to modulate faecal
levels of SCFA in a statistically significant way(64–66). Addition-
ally, Gibson et al. could not demonstrate an increase in faecal
SCFA levels after consumption of 15 g oligofructose/d(67). The
increased levels of bifidobacteria in the faeces could explain
the increased faecal acetic acid levels after WBE intake as
compared with placebo intake. In fact, in vitro studies have
demonstrated that different Bifidobacterium sp. can degrade
AXOS, thereby generating SCFA, mainly acetate and the
organic acid lactate(6,68). Bifidobacteria do not produce butyric
acid and a mechanism of cross-feeding with acetate- or lactate-
converting bacteria may be involved in increased colonic
butyric acid production(69,70). The levels of bacteria of the
Roseburia–E. rectale group and of the F. prausnitzii group
were determined given their butyric acid-producing
capacity(71). WBE intake did not increase faecal levels of the
Roseburia–E. rectale group or of the Faecalibacterium
group. However, the metabolic activity of the Roseburia–E.
rectale group or the Faecalibacterium group could be chan-
ged upon WBE administration, leading to an increase in buty-
ric acid-forming capacity, which cannot be detected using
FISH. In addition, using a new molecular approach, based
on analysis of the butytyl-CoA:acetate CoA transferase gene,
Louis et al. identified twenty novel operational taxonomic
units probably capable of producing butyrate(72). Hence, the
observed increase in butyrate production upon WBE intake
could be explained by an increase in the levels of novel,
still to be identified, butyrate-producing strains. The ability
of the different members of the gut community to compete
successfully depends on many traits besides their ability to uti-
lise certain substrates, such as their intrinsic growth rate, toler-
ance to colonic pH fluctuations and efficient binding to
substrate particles and gut surfaces(72).
Concomitant with the increased SCFA production, intake of
WBE at 10 g/d significantly decreased stool pH by about 0·2
units as compared with placebo intake. A more acidic gut
environment is reported to enhance the colonisation resist-
ance against pathogens(73), to reduce the formation of second-
ary bile acids(74) and to impair the activity of specific enzymes
such as proteases(75).
Intake of WBE at 10 g/d resulted in a marked reduction
of urinary p-cresol levels by 37 % as compared with the
p-cresol levels after placebo intake, which is indicative for a
reduction in colonic protein fermentation. The reduction
observed in the present study confirms previous results(10)
and is in agreement with foregoing studies in which a ben-
eficial modulation of the colonic ammonia metabolism
(another protein fermentation metabolite) was observed
after AXOS intake(36). Colonic fermentation of proteins results
in the formation of ammonia, nitrosamines, thiols and pheno-
lic compounds, which are generally believed to be potentially
harmful. Hence, reduction of colonic protein fermentation is
believed to be beneficial to human health(19).
Besides a small difference for lymphocyte percentage,
we found no difference in any of forty-four safety-related
blood parameters that were tested following WBE intake.
The difference in lymphocytes was not considered toxi-
cologically relevant since the observed difference was within
the normal range and not dose-dependent, and since WBE
intake did not affect the occurrence of adverse blood shifts
in this or any other blood parameter. Absence of adverse
effects on blood parameters was previously observed in a
smaller-scale intervention trial on healthy subjects with
WBE-like material(10).
Intake of WBE at doses up to 10 g/d did not affect bowel
habits. This is in agreement with a study in which intake of
inulin at 20 g/d by healthy volunteers did not modulate stool fre-
quency and consistency(65). In addition, intake of WBE at doses
up to 10 g/d had no effect on most of the eighteen gastrointes-
tinal symptoms surveyed. A mild increase of flatulence was
observed at intake of WBE at 10 g/d. Mild to moderate flatulence
was observed in some studies with other prebiotic compounds
such as inulin and fructo-oligosaccharides, which is caused by
the production of gases upon fermentation of the prebiotic
compound(34,65,76–79). On the other hand, a trend of decreased
occurrence frequency of constipation was noted at the high
WBE dose. Improvement of constipation symptoms has been
observed for other prebiotic compounds, such as xylo-oligosac-
charides(80) and inulin(66,81,82), yet these studies were generally
performed on constipated subjects.
The low incidence of gastrointestinal complaints and the
absence of adverse changes in haematology and clinical
blood chemistry parameters provide evidence for the excellent
tolerability and safety of WBE, complementing the results of
the in vitro and in vivo safety assessment of WBE(83).
We recommend that WBE should be taken in at the dose of
10 g/d, considering that consumption of WBE at this dosage
exerts the following beneficial effects on gut health par-
ameters: increased production of SCFA, reduction of protein
fermentation and increase of faecal bifidobacteria levels.
Moreover, WBE is well tolerated and does not cause adverse
effects at up to 10 g/d in healthy adult volunteers.
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